

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer ID6168**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders at scoping raised concerns that women are being diagnosed with muscle-invasive bladder cancer at a later stage than men. Stakeholders also raised equality of access with regards to treatment and that patients in rural areas and smaller hospitals have equal opportunity to access new treatments.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Timeliness of diagnosis is outside of the remit of NICE technology appraisals. The committee will consider all inequalities presented. Treatment accessibility due to geographical location is outside of the remit of NICE technology appraisals.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made to the scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders have been identified.

**Approved by Associate Director (name):** Ross Dent

**Date:** 08/04/2025